A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 31 Jan 2018
At a glance
- Drugs Dexamethasone (Primary) ; Pomalidomide (Primary) ; SL 401 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Stemline Therapeutics
- 25 Jan 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 25 Jan 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 06 Dec 2016 Results (n=2, data cut off :7-25-16) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology